Medication-related osteonecrosis of the jaw: A literature review

Kuroshima, Shinichiro; Sasaki, Makoto; Saeki, Takashi

doi:10.1016/j.job.2019.03.005

Cited by 90 publications

(79 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Considering the short time onset, they may be not related to denosumab use. Possible severe adverse events that may occur after long-term bisphosphonate or denosumab use are atypical femoral fracture and osteonecrosis of the jaw [33,34]; however, no subjects in this study presented those complications. Considering the low incidences of complications, a larger number of participants with longer treatment period are necessary to prove the safety and feasibility of the switching therapy.…”

Section: Discussionmentioning

confidence: 63%

Clinical effects of switching from minodronate to denosumab treatment in patients with postmenopausal osteoporosis: a retrospective study

et al. 2020

View full text Add to dashboard Cite

Background: Denosumab is a major treatment option for patients with postmenopausal osteoporosis; however, the evidence for its use is lacking. Therefore, in this 24-month retrospective study, we aimed to evaluate the effects of switching from minodronate (MIN) to denosumab in these patients. Methods: Patients with postmenopausal osteoporosis either switched from MIN to denosumab (Group 1; n = 32) or continued MIN treatment (Group 2; n = 24). Bone mineral density (BMD) of the lumbar spine (L2-L4) and femoral neck was assessed at baseline and every 6 months for 24 months. Serum bonespecific alkaline phosphatase (BAP) and N-terminal telopeptide were measured at baseline, 12 months, and 24 months. Results: Twenty-nine of the 32 patients (90.6%) in group 1 and all patients (24/24) in group 2 completed the 24-month follow-up. Switching from MIN to denosumab (Group 1) significantly increased lumbar BMD at 12, 18, and 24 months (6.1, 7.4, and 9.6%, respectively) and femoral neck BMD at 12, 18, and 24 months (2.8, 3.2, and 3.4%, respectively), whereas MIN continuous treatment (Group 2) showed no significant difference from baseline. Switching therapy also showed a significant decrease in serum BAP from baseline to 12 and 24 months (− 19.3 and − 26.5%, respectively) and serum NTX from baseline to 12 months (− 13.1%), whereas continuous MIN treatment failed to show any significant differences from baseline. Conclusion: Switching from MIN to denosumab in patients with postmenopausal osteoporosis showed clinical benefits with regard to BMD and bone turnover markers in comparison with continuous MIN treatment. It may therefore be a valid treatment option in the clinical setting.

show abstract

Section: Discussionmentioning

confidence: 63%

Clinical effects of switching from minodronate to denosumab treatment in patients with postmenopausal osteoporosis: a retrospective study

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Rarely, however, individuals taking bone resorption inhibitors present with medication-related osteonecrosis of the jaw (MRONJ), particularly those who have suffered invasive dental treatments, such as tooth extraction. MRONJ is mainly characterized by incomplete healing of oral mucosa, jaw osteonecrosis, and necrotic jaw bone exposure with increased risk of infection, and induces significant burden and dysfunction to patients that affect the overall individual’s health and quality of life [ 5 , 6 , 7 , 8 , 9 , 10 ].…”

Section: Introductionmentioning

confidence: 99%

“…Although MRONJ was first reported in 2003 by Marx [ 11 ], the cause and pathophysiological mechanisms of MRONJ are still unclear, and the treatment method has not been clearly defined. It is known that bone resorption inhibitors cause an excessive suppression of osteoclast activities, resulting in the inactivation of bone remodeling and the increased susceptibility for oral bacterial infection [ 7 , 8 , 9 ]. Moreover, inhibition of angiogenesis is another major hypothesis in MRONJ pathophysiology since osteonecrosis itself is classically considered an interruption in vascular supply [ 7 ].…”

Section: Introductionmentioning

confidence: 99%

BMP-2/β-TCP Local Delivery for Bone Regeneration in MRONJ-Like Mouse Model

Mikai

Ono

Tosa

et al. 2020

IJMS

View full text Add to dashboard Cite

Medication-related osteonecrosis of the jaw (MRONJ) is a severe pathological condition associated mainly with the long-term administration of bone resorption inhibitors, which are known to induce suppression of osteoclast activity and bone remodeling. Bone Morphogenetic Protein (BMP)-2 is known to be a strong inducer of bone remodeling, by directly regulating osteoblast differentiation and osteoclast activity. This study aimed to evaluate the effects of BMP-2 adsorbed onto beta-tricalcium phosphate (β-TCP), which is an osteoinductive bioceramic material and allows space retention, on the prevention and treatment of MRONJ in mice. Tooth extraction was performed after 3 weeks of zoledronate (ZA) and cyclophosphamide (CY) administration. For prevention studies, BMP-2/β-TCP was transplanted immediately after tooth extraction, and the mice were administered ZA and CY for an additional 4 weeks. The results showed that while the tooth extraction socket was mainly filled with a sparse tissue in the control group, bone formation was observed at the apex of the tooth extraction socket and was filled with a dense connective tissue rich in cellular components in the BMP-2/β-TCP transplanted group. For treatment studies, BMP-2/β-TCP was transplanted 2 weeks after tooth extraction, and bone formation was followed up for the subsequent 4 weeks under ZA and CY suspension. The results showed that although the tooth extraction socket was mainly filled with soft tissue in the control group, transplantation of BMP-2/β-TCP could significantly accelerate bone formation, as shown by immunohistochemical analysis for osteopontin, and reduce the bone necrosis in tooth extraction sockets. These data suggest that the combination of BMP-2/β-TCP could become a suitable therapy for the management of MRONJ.

show abstract

“…In theory, long-term bisphosphonate therapy would be conceivable-albeit potential side effects would then have to be weighed up [37].…”

Section: Antiresorptive Drugsmentioning

confidence: 99%

Response of Different Treatment Protocols to Treat Chronic Non-Bacterial Osteomyelitis (CNO) of the Mandible in Adult Patients: A Systematic Review

Timme

Bohner

Huss

et al. 2020

IJERPH

View full text Add to dashboard Cite

(1) Background: Chronic non-bacterial osteomyelitis (CNO) is an autoinflammatory bone disease of finally unknown etiology, which can occur alone or related with syndromes (chronic recurrent multifocal osteomyelitis—CRMO; synovitis, acne, pustulosis, hyperostosis and osteitis syndrome—SAPHO). The involvement of the mandible is rather rare. (2) Methods: We carried out a systematic literature search on CNO with mandibular involvement, according to the “Preferred Reporting Items for Systematic Reviews and Meta-Analyses” (PRISMA) guidelines, considering the different synonyms for CNO, with a special focus on therapy. (3) Results: Finally, only four studies could be included. A total of 36 patients were treated in these studies—therefore, at most, only tendencies could be identified. The therapy in the included works was inconsistent. Various therapies could alleviate the symptoms of the disease. A complete remission could only rarely be observed and is also to be viewed against the background of the fluctuating character of the disease. The success of one-off interventions is unlikely overall, and the need for long-term therapies seems to be indicated. Non-steroidal anti-inflammatory drugs (NSAIDs) were not part of any effective therapy. Surgical therapy should not be the first choice. (4) Conclusions: In summary, no evidence-based therapy recommendation can be given today. For the future, systematic clinical trials on therapy for CNO are desirable.

show abstract

Medication-related osteonecrosis of the jaw: A literature review

Cited by 90 publications

References 51 publications

Clinical effects of switching from minodronate to denosumab treatment in patients with postmenopausal osteoporosis: a retrospective study

Clinical effects of switching from minodronate to denosumab treatment in patients with postmenopausal osteoporosis: a retrospective study

BMP-2/β-TCP Local Delivery for Bone Regeneration in MRONJ-Like Mouse Model

Response of Different Treatment Protocols to Treat Chronic Non-Bacterial Osteomyelitis (CNO) of the Mandible in Adult Patients: A Systematic Review

Contact Info

Product

Resources

About